Carpagnano et al. indicated that the concentrations of inflammatory markers such as cytokines including interleukin-6 (IL-6) and vascular stimulating factor (endothelin-1) were significantly different in the EBCs of patients with lung cancer than controls, and the same difference between the various stages of NSCLC was also found. The gene discussed is IL6; the disease is lung carcinoma.